TREATMENT RELATED SECONDARY MALIGNANCY

TREATMENT RELATED SECONDARY MALIGNANCY was reported 203 times

These drug classes are most commonly taken by patients reporting TREATMENT RELATED SECONDARY MALIGNANCY:

# Drug Count
0 Alkylating Drug [EPC] 94
1 Folate Analog Metabolic Inhibitor [EPC] 52
2 Nucleoside Metabolic Inhibitor [EPC] 48
3 Topoisomerase Inhibitor [EPC] 45
4 Platinum-based Drug [EPC] 38
5 Corticosteroid [EPC] 33
6 Microtubule Inhibitor [EPC] 14
7 Actinomycin [EPC] 13
8 CD20-directed Cytolytic Antibody [EPC] 10
9 Antimetabolite [EPC] 8
10 Thalidomide Analog [EPC] 5
11 Leukocyte Growth Factor [EPC] 4
12 Purine Antimetabolite [EPC] 4
13 Retinoid [EPC] 4
14 Vitamin C [EPC] 4
15 Azole Antifungal [EPC] 3
16 Calcineurin Inhibitor Immunosuppressant [EPC] 3
17 Nonsteroidal Anti-inflammatory Drug [EPC] 3
18 Proteasome Inhibitor [EPC] 3
19 Vitamin B12 [EPC] 3
20 Vitamin D [EPC] 3
21 Fluoroquinolone Antibacterial [EPC] 2
22 HER2/neu Receptor Antagonist [EPC] 2
23 Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 2
24 Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 2
25 Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 2
26 Kinase Inhibitor [EPC] 2
27 Tumor Necrosis Factor Blocker [EPC] 2
28 Vascular Endothelial Growth Factor Inhibitor [EPC] 2
29 Aminosalicylate [EPC] 1
30 Angiotensin 2 Receptor Blocker [EPC] 1
31 Aromatase Inhibitor [EPC] 1
32 Benzodiazepine [EPC] 1
33 CD33-directed Immunoconjugate [EPC] 1
34 CD52-directed Cytolytic Antibody [EPC] 1
35 Dihydrofolate Reductase Inhibitor Antibacterial [EPC] 1
36 Erythropoiesis-stimulating Agent [EPC] 1
37 Estrogen [EPC] 1
38 Histamine-2 Receptor Antagonist [EPC] 1
39 Nicotinic Acid [EPC] 1
40 Platelet Aggregation Inhibitor [EPC] 1
41 Proton Pump Inhibitor [EPC] 1
42 Sulfonamide Antimicrobial [EPC] 1
43 Sulfonylurea [EPC] 1
44 Xanthine Oxidase Inhibitor [EPC] 1
45 beta-Adrenergic Blocker [EPC] 1
46 mTOR Inhibitor Immunosuppressant [EPC] 1